Shares in AstraZeneca (AZN.L) gain 2.6 percent after European regulators recommended its drug Iressa for certain lung cancer patients late on Thursday. Hopes for robust first quarter results on April 30 also help the stock, analysts say.
Shares in AstraZeneca (AZN.L) gain 2.6 percent after European regulators recommended its drug Iressa for certain lung cancer patients late on Thursday. Hopes for robust first quarter results on April 30 also help the stock, analysts say.
